Lexicon Pharmaceuticals (LXRX) Current Deferred Revenue (2010 - 2025)

Lexicon Pharmaceuticals (LXRX) posted quarterly Current Deferred Revenue of $4.3 million for Q3 2025, down 75.35% quarter-over-quarter from $17.5 million in Q2 2025.

Lexicon Pharmaceuticals (LXRX) Current Deferred Revenue (2010 - 2025) Analysis & Trends

Lexicon Pharmaceuticals (LXRX) has reported Current Deferred Revenue for 11 consecutive years, with $4.3 million the latest figure, recorded in Q3 2025.

  • In Q3 2025, Current Deferred Revenue changed N/A year-over-year to $4.3 million; the TTM figure through Sep 2025 stood at $4.3 million (changed N/A YoY), while the FY2018 annual figure was $2.3 million, down 94.2% from the prior year.
  • Current Deferred Revenue fell to $4.3 million in Q3 2025 per LXRX's latest filing, from $17.5 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $45.0 million in Q1 2025 and bottomed at $4.3 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Lexicon Pharmaceuticals 1.04 Bn 846.13 Mn 653,000.00

Historic Data

Download Data
DateValue
Sep 30, 2025 4.30 Mn
Jun 30, 2025 17.46 Mn
Mar 31, 2025 45.00 Mn
Sep 30, 2019 1.12 Mn
Jun 30, 2019 2.24 Mn
Mar 31, 2019 2.43 Mn
Dec 31, 2018 2.34 Mn
Sep 30, 2018 2.12 Mn
Jun 30, 2018 5.12 Mn
Mar 31, 2018 7.44 Mn
Dec 31, 2017 40.35 Mn
Sep 30, 2017 48.74 Mn
Jun 30, 2017 63.20 Mn
Mar 31, 2017 69.17 Mn
Dec 31, 2016 63.37 Mn
Sep 30, 2016 78.87 Mn
Jun 30, 2016 61.53 Mn
Mar 31, 2016 70.76 Mn
Dec 31, 2015 76.50 Mn
Sep 30, 2015 1.74 Mn